InflaRx Appoints KPMG as New Auditor Following Shareholder Approval.
ByAinvest
Friday, Jun 27, 2025 9:08 pm ET1min read
IFRX--
InflaRx has appointed KPMG as its new auditor following shareholder approval. The decision was made after EY, the previous auditor, was transitioned out. InflaRx is a biotechnology company developing anti-inflammatory therapeutics. The company's financial performance has been weak, with negative profitability and cash flow issues. Analyst ratings and valuation metrics also highlight concerns.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet